A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.
Fiche publication
Date publication
décembre 2022
Journal
Breast cancer research and treatment
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel, Pr PETIT Thierry, Pr PIVOT Xavier, Dr DEMARCHI Martin, Dr COLIAT Pierre, Dr BENDER Laura
Tous les auteurs :
Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P
Lien Pubmed
Résumé
A 4-weekly schedule of pegylated liposomal doxorubicin (PLD) has been approved for the treatment of metastatic breast cancer (MBC). Phase II trials have suggested interest in a 2-weekly regimen. This study aimed to compare the efficacy and safety of these two schedules.
Mots clés
Anthracyclines, Metastatic breast cancer, Pegylated liposomal doxorubicin, Propensity score, Schedule
Référence
Breast Cancer Res Treat. 2022 12 23;: